| Title |
Could lysine supplementation prevent Alzheimer’s dementia? A novel hypothesis
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, October 2010
|
| DOI | 10.2147/ndt.s14338 |
| Pubmed ID | |
| Authors |
Robert N Rubey |
| Abstract |
There is a growing body of evidence that implicates the herpes simplex type 1 virus (HSV-1) in the development of Alzheimer's dementia (AD). HSV-1 has been found to be present in the cerebrum of the great majority of older adults, and in many of the same areas of the brain that are affected by AD. When active, the virus may contribute to the formation of the neuro-fibrillary tangles and amyloid plaques characteristic of AD. Like AD, HSV-1 encephalitis may cause long term memory loss. HSV-1 replication is suppressed in lysine-rich/arginine - poor environments, and population studies suggest that diets high in lysine and low in arginine may be associated with lower rates of AD. There are no prospective studies of the efficacy of lysine supplementation to prevent or reduce the incidence of AD. Supplementation with adequate doses of lysine could prevent the development of AD. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 25% |
| United States | 1 | 25% |
| Australia | 1 | 25% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 2% |
| Unknown | 42 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 9 | 21% |
| Student > Bachelor | 5 | 12% |
| Student > Master | 5 | 12% |
| Researcher | 4 | 9% |
| Student > Postgraduate | 4 | 9% |
| Other | 7 | 16% |
| Unknown | 9 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 23% |
| Psychology | 4 | 9% |
| Nursing and Health Professions | 4 | 9% |
| Chemistry | 3 | 7% |
| Agricultural and Biological Sciences | 2 | 5% |
| Other | 8 | 19% |
| Unknown | 12 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 October 2023.
All research outputs
#5,306,356
of 25,621,213 outputs
Outputs from Neuropsychiatric Disease and Treatment
#739
of 3,140 outputs
Outputs of similar age
#22,652
of 108,822 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#2
of 9 outputs
Altmetric has tracked 25,621,213 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,140 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 108,822 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 7 of them.